1 To elucidate the structural features required for selective and potent action of dermenkephalin at the 6-opioid receptor, a series of analogues of dermenkephalin and dermorphin were tested for their effectiveness in depressing electrically-evoked contractions of the vas deferens of the hamster (6-opioid receptors) and the guinea-pig myenteric plexus-longitudinal muscle preparation (u-and K-opioid receptors). 2 Dermenkephalin was more selective and more potent at 6-receptors than the 6-ligand [D-Pen2, DPen5]-enkephalin. The responses to dermenkephalin in the hamster vas deferens were increased by addition of peptidase inhibitors; the maximum effect was obtained with 3juM thiorphan.
Introduction
Most of the endogenous opioid peptides arise from the processing of one of three distinct precursors, proopiomelanocortin (Nakanishi et al., 1979) , pro-enkephalin or pro-dynorphin (Kakidani et al., 1982) .
Each of these peptides interacts with more than one type of opioid receptor (Kosterlitz, 1985) which makes it difficult to explore the physiological role of the p-, 6-and K-opioid receptors. A fourth group of opioid peptides has been found to be present in the skin of frogs belonging to the subfamily Phyllomedusinae Erspamer & Melchiorri, 1983; Erspamer et al., 1989) . These heptapeptides, dermorphin , dermenkephalin Amiche et al., 1989) [also known as deltorphin or dermorphin gene-associated peptide (Lazarus et al., 1989) ], deltorphin I and deltorphin II (Erspamer et al., 1989; Richter et al., 1990) , are devoid of structural homology with mammalian opioids and contain a common N-terminal sequence Tyr-D-aa-Phe, in which 'D-aa' is either D-Ala or D-Met. Thus, they are unique among peptides synthesized by animal cells in having a D-amino acid in their sequence, even though the D-residue is encoded by the usual L-amino acid codons in the cDNA (Richter et al., 1987) .
These amphibian peptides have singular pharmacological patterns since they are selective for one of the opioid receptor types. Dermorphin, Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, has high affinity and selectivity for the yu-opioid receptor (Broccardo et al., 1981; Yamashiro et al., 1983; Rossi et al., 1986; Amiche et al., 1990) . In contrast, dermenkephalin, Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2, and the deltorphins I and II, Tyr-D-Ala-Phe-aa-Val-Val-Gly-NH2 where 'aa' is either Asp or Glu, have high affinity and selectivity for the 6-opioid receptor Erspamer et al., 1989; Kreil et al., 1989; Lazarus et al., 1989) ; their affinities and selectivities are the equal of, or are superior to, those of the (Mosberg et al., 1983) , (OtBu) , Leu5]-enkephalyl-Thr6 and [DSer2, (OtBu) , Leu5]-enkephalyl-Thr6 (Delay-Goyet et al., 1988) .
In binding assays, it has been demonstrated that the Cterminal tripeptide of dermenkephalin is critical in specifying the 6-selectivity of the molecule. Moreover, the preferred opioid binding of dermorphin is changed from the p-site to the 6-site when the C-terminal tripeptide of dermorphin is replaced by the C-terminal tripeptide of dermenkephalin (Sagan et al., 1989a,b) . However, binding assays provide information only on the interaction of a comp'ound with the recognition site of a receptor but they do not determine whether a peptide acts as agonist or antagonist. In the present investigation, we have determined with bioassays in isolated tissues, the opioid activities of a series of dermenkephalin and dermorphin analogues. The main assay preparations used were the myenteric plexus-longitudinal muscle of the guineapig small intestine which has p-and Kc-opioid receptors but no 6-receptors (Lord et al., 1977) and the hamster vas deferens which contains 6-receptors but not pI-or K-receptors (McKnight et al., 1985) ; the mouse vas deferens which contains u-, 6-and K-receptors (Hughes et al., 1975; Schultz & Wuster, 1981 ) also was used. Since the binding studies have shown that dermorphin and dermenkephalin have negligible K-affinity , comparison of the results obtained in the myenteric plexus with those in the hamster vas deferens should demonstrate the amino acids required for selective and potent agonist action at the ,u-and 6-opioid receptors. The selective K-opioid antagonist norbinaltorphimine was used to confirm that none of the analogues had K-opioid activity (Portoghese et al., 1987) .
Methods

Bioassays in isolated tissues
The myenteric plexus-longitudinal muscle preparation of the guinea-pig small intestine and the vasa deferentia of the hamster and the mouse were set up for field stimulation in 3 ml siliconised organ baths as described previously (McKnight et al., 1983; 1985) . Dunkin-Hartley guinea-pigs (Tuck), Golden Syrian hamsters (MB strain; Intersimian) and TO mice (Tuck) were used. When the myenteric plexus preparation was used, hexamethonium bromide (70pM; May & Baker), mepyramine maleate (0.13 pm; May & Baker) and choline chloride (20mM; BDH) were added to the Krebs solution (Kosterlitz & Watt, 1968) .
Complete dose-response curves were constructed for each of the peptides; potencies were expressed as IC50 values (nM). Between each dose of the peptide under investigation, a standard agonist was used to monitor any changes in tissue sensitivity during the experimentation. The 6-opioid agonist [DPen2, D-Pen5]-enkephalin (Mosberg et al., 1983) was the standard for the vasa deferentia and the u-agonist [D-Ala2, MePhe4,Gly-ol5]-enkephalin (Kosterlitz & Paterson, 1981) for the myenteric plexus. The possibility of dermenkephalin or dermorphin having any antagonist activity was estimated by the 'single dose' method of Kosterlitz & Watt (1968) .
Since it is well known that many opioid peptides are rapidly degraded by tissue peptidases, the potencies of dermorphin, dermenkephalin and their analogues were determined in the hamster vasa deferentia before and after the addition of a cocktail of peptidase inhibitors: bestatin (10uM), amastatin (10pM), thiorphan (10pM) and captopril (10pM) (McKnight et al., 1983; 1985) . In a few experiments the effects of different concentrations of individual peptidase inhibitors were also examined. The tissues were exposed to the peptidase inhibitors for at least 20min before reassessing activity of the opioid compounds; full dose-response curves were constructed before and after addition of antipeptidases.
In preliminary experiments, it was found that in the myenteric plexus and in the mouse vas deferens the potencies of dermenkephalin and dermorphin were unchanged by inhibition of tissue peptidases. Consequently, full dose-response curves for the analogues were not constructed in either tissue after inhibition of peptidases; at the end of each assay a single concentration of analogue was added to the tissue after the addition of peptidase inhibitors to the bathing Krebs solution.
Peptides and drugs
Dermenkephalin, dermorphin and related peptides (Table 1) were prepared by stepwise solid phase synthesis as described (Amiche et al., 1988) . After treatment with liquid HF and ether extraction, the peptides were purified by a combination of Sephadex gel filtration, ion exchange chromatography and preparative high performance liquid chromatography (h.p.l.c.). Homogeneity of the synthetic peptides was assessed by analytical h.p.l.c., thin layer chromatography, amino acid analysis and fast atomic bombardment mass spectrometry (Nicolas et al., 1986) . Stock solutions of the peptides were prepared in distilled water and stored at -250C. Drugs were added to the bath from siliconised glass microsyringes in volumes not exceeding 50,ul. 
Results
Opioid activity ofdermenkephalin and dermorphin in bioassays Dermenkephalin had very low agonist activity in the guineapig myenteric plexus preparation (IC50 = 5000nM) but was much more active in the hamster vas deferens ( Table 2 ). The inhibitory effects of dermenkephalin in the hamster vas deferens were blocked by either the selective 6-opioid antagonist naltrindole (Portoghese et al., 1988; Figure 1) or by lOOnM naloxone; 10nm naloxone did not antagonize the action of dermenkephalin (data not shown).
Dermorphin was very potent in the myenteric plexus preparation but it was inactive in the hamster vas deferens ( Table  2 ). The inhibitory effects in the myenteric plexus were antagonized by a low concentration of naloxone (10 nM), indicative of an action at ,-receptors but they were not antagonized by the selective K-opioid antagonist nor-binaltorphimine (10 nM).
Dermorphin and dermenkephalin were equiactive in the mouse vas deferens with IC50 values of -2 nm (Table 2) . Neither of the peptides had antagonist activity in any of the bioassay tissues.
There is no evidence from the bioassays that either of the compounds has affinity for K-receptors. Therefore, the ratio of the IC50 value in the guinea-pig myenteric plexus to the IC50 value in the hamster vas deferens is a measure of the degree of selectivity of the peptide for the 6-receptor or for the preceptor. If the ratio is high, e.g. 385 for dermenkephalin, the 
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Effects ofpeptidase inhibitors on the agonist potency of dermenkephalin and dermorphin
The combination of peptidase inhibitors, bestatin, amastatin, captopril and thiorphan, increased the potency of dermenkephalin in the hamster vas deferens about 30 fold (Table 2) . Therefore in the hamster vas deferens, the activities of all peptides were determined before and after the addition of antipeptidases (Table 2 ). In a few experiments different combinations and concentrations of peptidase inhibitors were examined in the hamster vas deferens. Thiorphan by itself was responsible for protection of dermenkephalin, the maximum effect being achieved by 3 AM (Figure 2 ). In contrast, in the myenteric plexus and the mouse vas deferens the potencies of dermenkephalin, dermorphin and their analogues were unchanged by inhibition of peptidases.
Agonist activity ofsome dermenkephalin analogues in bioassays
In the myenteric plexus preparation, the selective K-opioid antagonist nor-binaltorphine (10 nM) had no effect on the agonist activity of the dermenkephalin analogues added to the organ baths in concentrations about their ICO value. Thus, since these analogues are devoid of K-agonist activity, comparison of the data from the myenteric plexus with those from the hamster vas deferens permits the direct correlation of p-potency with 3-potency.
In the myenteric plexus, the hexapeptide dermenkephalin-(1-6)-NH2 was 11 times more potent than dermenkephalin whereas, in the 3-selective hamster vas deferens, dermenkephalin was 3 times more potent than dermenkephalin-(1-6)-NH2 (Table 2) . Hence, the ratio of 3-activity to p-activity was 385 for dermenkephalin but only 11 for dermenkephalin-(1-6)-NH2 (Table 2 ). Further shortening of the peptide to dermenkephalin-(14)-NH2 resulted in a complete loss of 3-activity whereas the p-potency remained similar to that of dermenkephalin-(1-6)-NH2 (Table 2) . Thus, for dermenkephalin-(1-4-NH2 the ratio of 3-to p-activity is less than 0.02. [Dermenkephalin] (nM) Figure 2 The effects of peptidase inhibitors on the agonist activity of dermenkephalin in the hamster vas deferens; (0) (Table 2) . Interestingly, both dermenkephalin-(1-6)NH2 and [Asn7]-dermenkephalin have almost identical activity ratios and 3-receptor potencies ( Table  2) .
The importance of the C-terminal region of dermenkephalin for opioid receptor selectivity and pharmacological potency is demonstrated further by comparing the activities of dermenkephalin and dermorphin to those of the hybrid molecules [Leu5,Met6,Asp7]-dermorphin and [His4,Leu5,Met6,Asp7]-dermorphin, i.e. dermorphin-(1-4)-dermenkephalin-(5-7) and dermorphin-(1-3)-dermenkephalin-(4-7) ( Table 2) . Substitution of the C-terminal tripeptide of dermorphin with the Cterminal tripeptide of dermenkephalin abolished the ,ureceptor preference of dermorphin, the hybrid peptide being equiactive in the hamster vas deferens and the myenteric plexus preparation ( Table 2 ). The IC50 for [Leu5,Met6, Asp7]-dermorphin in the hamster vas deferens was 16nm, the same as that for dermenkephalin. Replacement of the Cterminal tetrapeptide of dermorphin with the C-terminal tetrapeptide of dermenkephalin caused no change in 3-activity, when compared to the tripeptide hybrid but the fuactivity was less with an IC50 value of 260 nm. Thus, [His4, Leu5,Met6,Asp7]-dermorphin has a preference for the 3-opioid receptor (Table 2 ).
The role of the D-amino acids
The relationship between opioid receptor selectivity and the stereochemistry of the second amino acid of dermenkephalin and dermorphin was assessed by replacing the naturallyoccurring D-amino acids by the L-amino acid. [L-Met2]-dermenkephalin was inactive in the hamster vas deferens and in the guinea-pig myenteric plexus preparation (Table 2) . Similar results were obtained with [L-Ala2]-dermorphin.
Whether the D-configuration is of importance for determining folding of thse molecules or confers resistance to proteolysis, has been considered by measuring agonist activity in the presence of protease inhibitors. In the hamster, the 3-activity of dermenkephalin was increased 30 fold by addition of peptidase inhibitors which had barely any effect on [L-Met2]-dermenkephalin, as the IC50 value changed from >10,000 nm to 7000nm ( Table 2 ). The potencies of dermorphin and [L-Ala2]-dermorphin in the myenteric plexus were unchanged by peptidase inhibition.
The influence of the stereochemistry of the sixth amino acid of dermenkephalin was investigated by changing L-Met6 to D-Met6. In the hamster vas deferens [D-Met6]-dermenkephalin had only 0.07% the activity of dermenkephalin (Table 2) . There was a small increase in f-receptor potency in the myenteric plexus from 5000 nm to 2000 nm.
Discussion
The results of this investigation confirm the high potency and selectivity of dermenkephalin for 3-opioid receptors and of dermorphin for P-receptors. Of the bioassay tissues used, the hamster vas deferens contains only 3-receptors but the myenteric plexus has It-and K-receptors. Since dermorphin, dermenkephalin and their analogues have no activity at K-receptors  (Schultz & Wuster, 1981) , is not a reliable tissue in which to assess agonist potency and the receptor selectivity of opioids (Table 2) .
We have used the isolated tissue bioassays to determine the opioid activity of some analogues of dermorphin and dermenkephalin and thus elucidate the structural features required for the selective and potent action of dermenkephalin at 3-receptors. It has been proposed by Schwyzer (Schwyzer, 1986 ) that opioid peptides have a common N-terminal sequence which is the 'message' segment triggering the receptor responses but have different C-terminal 'address' segments responsible for their receptor type preference. It is of interest that dermorphin and dermenkephalin have similar N-terminal sequences, Tyr-D-aa-Phe, but they have distinct C-terminal regions. Furthermore, n.m.r. studies have shown that the Nterminal regions of dermorphin and dermenkephalin have similar conformational features (Temussi et al., 1989) . Therefore, the side-chains of the amino acids in the C-terminal region, and their sequence, should be the only factors directing receptor selectivity of amphibian skin opioid peptides.
The present results confirm the data from binding assays in homogenates of rat brain (Sagan et al., 1989a,b) that agonist potency and discrimination between g-and 3-opioid receptors depends on the C-terminal sequence of dermenkephalin. Since dermenkephalin-(1-4)NH2 retains less than 0.4% of the 3-receptor potency of dermenkephalin-(1-6)-NH2, the presence of Leu5 and/or Met6 is important for the opioid activity of dermenkephalin. The fact that dermenkephalin41-4)-NH2 and dermenkephalin-(1-6)-NH2 have comparable potencies at the Preceptor, suggests that the side-chains of Leu5 and/or Met6 are critical for the full expression of the agonist activity of dermenkephalin. The finding that changing the stereochemistry of the sixth amino acid by replacing L-Met6 by D-Met6 causes a loss of 3-potency, implies that both the constitution and the proper orientation of the C-terminal tripeptide of dermenkephalin are major contributors to receptor selectivity.
Interestingly, dermenkephalin-(1-6)-NH2 and [Asn7]-dermenkephalin which are equipotent in the hamster vas deferens, also have similar ratios of f-activity to 3-activity, 11 and 19. This indicates that the negatively charged side-chain of the endogenous Asp7 makes a significant contribution to the 3-addressing ability of the C-terminal region. This is in accordance with Schwyzer's model of membrane requirement for opioid selection in which the 3-receptor would be less accessible to positively charged than to neutral opioid agonists. However, since deletion or modification of Asp7 mainly affects the f-potency (which is increased) rather than the 3-potency of dermenkephalin, the contribution of Asp7 to 3-selectivity is due to its depressant effect on affinity for the preceptor. The importance of the C-terminal sequence of dermenkephalin in determining receptor selection and agonist potency is supported by our finding that it is possible to invert the selectivity of dermorphin, from f-activity > 3-activity to 3-activity > fl-activity, by exchanging its C-terminal part with that of dermenkephalin. A decisive shift towards 3-receptor selectivity was obtained by replacing the C-terminal tetrapeptide of dermorphin with the C-terminal tetrapeptide of dermenkephalin. The resulting hybrid peptide, [His4,Leu5,Met6,Asp7]-dermorphin, exhibited good selectivity and high potency at 3-receptors. This observation shows that His4 is significantly involved in directing dermenkephalin towards the 3-receptor. Therefore, the role of the membrane in determining opioid receptor selectivity may involve only the 'address' of the Cterminal region of dermenkephalin.
The configuration of the Met-residue in position 2 makes a major contribution to pharmacological potency since [LMet2]-dermenkephalin is inactive in the hamster vas deferens as well as in the myenteric plexus preparation. The Dconfiguration is of importance in determining active folding of these molecules rather than conferring resistance to peptidases as the potency of [L-Met2]-dermenkephalin was unaffected by protease inhibitors.
In conclusion, these findings are consistent with a moderate but definite role for the side-chains of D-Met2 and His4 in directing selectivity of dermenkephalin. They demonstrate that a negative charge at the C-terminus of dermenkephalin is important for 6-opioid receptor selectivity. Furthermore, the data strongly suggest that Leu5 and/or Met6 are involved in ensuring high agonist potency at the 5-site rather than in controlling receptor selectivity. Thus, dermenkephalin, dermorphin and their analogues may provide a starting point for the design of selective agonists which may be used for the exploration of the ill-defined physiological roles of ju-and 5-opioid receptors.
